The Expression of SOCS and NF-κB p65 in Hypopharyngeal Carcinoma
Background: Hypopharyngeal carcinoma is one of the most common types of head and neck tumors. Suppressers of cytokine signalling (SOCS) family members are key regulators of cytokine homeostasis, they play important roles in the process of cell proliferation, differentiation, maturation and apoptosis, and participate in the occurrence and development of tumor. The abnormal activation of NF-κB is an important feature of the tumor. The aim of this study was to investigate the relationships among SOCS, NF-κB p65 and hypopharyngeal carcinoma development.C
Methods: We included 72 hypopharyngeal cancer patients and 9 swallow cyst patients. The patients were recruited at The Second Hospital of Shandong University (Jinan, China) between 2014 and 2016. The mRNA and protein expression levels of SOCS-1, SOCS-3 and NF-κB p65 in hypopharyngeal carcinoma tissues, paracancerous tissues and control tissues were detected by RT-PCR and Western blot analysis, respectively.
Results: Hypopharyngeal carcinoma tissues had lower level expression of SOCS-1 and SOCS-3 than pericarcinoma tissues, but there was no significant difference, while cancer tissues had significantly higher level expression of NF-κB p65 than that of pericarcinoma tissues (0.412±0.266, 0.281±0.231, t=2.969, P=0.004). The early stage patients had striking higher level expression of SOCS-1 and SOCS-3 than that in advanced stages (F=16.202, P<0.001; F=52.295, P<0.001), while the expression of NF-κB p65 in early stages had lower level than that in advanced stages (F=3.383, P=0.04).
Conclusion: SOCS-1, SOCS-3 may be protective factors while NF-κB p65 could be a harmful factor in hypopharyngeal carcinoma.
2. Li Z, Metze D, Nashan D et al (2004). Expression of SOCS-1, suppressor of cytokine signaling-1, in human melanoma. J Invest Dermatol,123(4):737-45.
3. Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A (2013). SOCS, inflammation, and cancer. JAKSTAT, 2(3):e24053.
4. Starr R, Willson TA, Viney EM et al (1997). A family of cytokine-inducible inhibitors of signalling. Nature,387(6636):917-21.
5. Chen XP, Losman JA, Rothman P (2000). SOCS proteins, regulators of intracellular signaling. Immunity,13(3):287-90.
6. Linossi EM, Nicholson SE (2015). Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins. Immunol Rev, 266(1):123-33.
7. Tas SW, Vervoodeldonk MJ, Tak PP (2009). Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory dieseases and cancer. Curr Gene Ther,9(3):160-70.
8. Luo JL, Kamata H, Karin M (2005). IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. J Clin Invest,115(10):2625-32.
9. Fujimoto M, Naka T (2010). SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. Gastroenterol Res Pract, 2010: 470468.
10. Vargas-Alarcon G, Posadas-Sanchez R, Posadas-Romero C et al (2014). Association of the suppressor of cytokine signaling 1 (SOCS1) gene polymorphisms with acute coronary syndrome in Mexican patients. Mol Immunol, 62(1):137-41.
11. Hamedi M, Bergmeier LA, Hagi-Pavli E et al (2014). Differential expression of suppressor of cytokine signalling proteins in Behcet's disease. Scand J Immunol, 80(5):369-76.
12. Babon JJ, Kershaw NJ, Murphy JM et al (2012). Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity,36(2):239-50.
13. Kiu H, Nicholson SE (2012). Biology and significance of the JAK/STAT signalling pathways. Growth Factors,30(2):88-106.
14. Kershaw NJ, Murphy JM, Liau NP et al (2013). SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol, 20(4):469-76.
15. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A (2011). Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol, 31(5):980-5.
16. Sutherland KD, Lindeman GJ, Choong DY et al (2004). Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene, 23(46):7726-33.
17. Sasi W, Jiang WG, Sharma A, Mokbel K (2010). Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer, 10:178.
18. Chu PY, Yeh CM, Hsu NC et al (2010). Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly,140:w13065.
19. Zhang J, Li H, Yu JP et al (2012). Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer,130(9):1971-80.
20. Li G, Xu J, Wang Z et al (2015). Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol,141(3):443-52.
21. Wu D, Wu P, Zhao L et al (2015). NF-kappaB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 94(40):e1687.
22. Annunziata CM, Stavnes HT, Kleinberg L et al (2010). Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer, 116(13):3276-84.
Copyright (c) 2018 Iranian Journal of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.